---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059717"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:02:06.334396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q3 cash $511M, darovasertib shows 42% ORR in 1L HLA-A2(-) MUM; registrational trial ongoing

## Summary
- Cash, cash equivalents and marketable securities of $511.1M as of Sep 30, 2023; plus $134.7M net proceeds from follow-on and $10M GSK milestone receivable.
- Darovasertib + crizotinib in 1L HLA-A2(-) MUM: ORR 42%, median PFS 7.1 months; Phase 2/3 registrational trial ongoing with >50 sites planned.
- Darovasertib neoadjuvant in primary UM: 50% eye preservation rate (3/6 evaluable), tumor shrinkage in 83% of evaluable patients.
- IDE161 received FDA Fast Track for BRCA1/2 ovarian and breast cancer; Phase 1 expansion initiated in HRD+ tumors.
- IND clearance for GSK101 (Pol Theta) triggered $7M milestone; Werner Helicase DC selected with $3M milestone; IND targeted in 2024.

## SEC filing metadata
- accession: 0000950170-23-059717
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/0000950170-23-059717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/idya-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059717
- JSON: https://secwatch.observer/filing/0000950170-23-059717.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059717.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: announced its financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/0000950170-23-059717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.